Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
mTOR inhibitor |
| gptkbp:approvalYear |
2007
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EG10
|
| gptkbp:brand |
gptkb:Torisel
|
| gptkbp:CASNumber |
gptkb:162635-04-3
|
| gptkbp:category |
antineoplastic agent
immunosuppressant |
| gptkbp:chemicalFormula |
C56H87NO16
|
| gptkbp:contraindication |
hypersensitivity to temsirolimus
|
| gptkbp:developedBy |
gptkb:Wyeth_Pharmaceuticals
|
| gptkbp:eliminationHalfLife |
17.3 hours
|
| gptkbp:excretion |
urine
feces |
| https://www.w3.org/2000/01/rdf-schema#label |
temsirolimus
|
| gptkbp:interactsWith |
CYP3A4 inhibitors
CYP3A4 inducers |
| gptkbp:IUPACName |
(1R,9S,12S,15R,18R,19E,21R,23S,24S,25R,27R,34aS)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethylidene]-15,23,27-trimethoxy-13,16,20,22,28,29,30,31,32,33,34,34a-dodecahydro-1H,11H,17H,35H-2,4,10,14,36-trioxacyclooctatriacontine-3,5,7,9,11,13,15,17,19,21,23,25,27,29,31,33-hexone
|
| gptkbp:KEGGID |
gptkb:D06013
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits mTOR
|
| gptkbp:metabolism |
gptkb:sirolimus
liver |
| gptkbp:molecularWeight |
1030.3 g/mol
|
| gptkbp:origin |
semisynthetic derivative of sirolimus
|
| gptkbp:pregnancyCategory |
D
D (US) |
| gptkbp:proteinBinding |
87%
|
| gptkbp:PubChem_CID |
gptkb:DB06287
gptkb:CHEMBL1201197 6918283 |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:anemia
nausea fatigue rash hyperglycemia hyperlipidemia mucositis |
| gptkbp:storage |
2–8°C
|
| gptkbp:synonym |
gptkb:CCI-779
gptkb:NSC_683864 gptkb:Torisel |
| gptkbp:UNII |
7LJ087RS6F
|
| gptkbp:usedFor |
renal cell carcinoma
|
| gptkbp:bfsParent |
gptkb:mTOR_pathway
gptkb:Afinitor |
| gptkbp:bfsLayer |
5
|